ResMed Cash Flow from Operating Activities 2010-2025 | RMD

ResMed cash flow from operating activities for the twelve months ending June 30, 2025 was $3.924B, a 22.33% increase year-over-year.

  • ResMed annual cash flow from operating activities for 2025 was $1.752B, a 25% increase from 2024.
  • ResMed annual cash flow from operating activities for 2024 was $1.401B, a 102.11% increase from 2023.
  • ResMed annual cash flow from operating activities for 2023 was $0.693B, a 97.44% increase from 2022.

ResMed Cash Flow from Operating Activities 2010-2025 | RMD

  • ResMed annual cash flow from operating activities for 2025 was $1.752B, a 25% increase from 2024.
  • ResMed annual cash flow from operating activities for 2024 was $1.401B, a 102.11% increase from 2023.
  • ResMed annual cash flow from operating activities for 2023 was $0.693B, a 97.44% increase from 2022.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$230.9B
Boston Scientific (BSX)$156.3B
Stryker (SYK)$149.6B
EssilorLuxottica (ESLOY)$141.3B
Medtronic (MDT)$119B
Lonza Group Ag (LZAGY)$49.8B
Haleon (HLN)$43.9B
Agilent Technologies (A)$35.7B
GE HealthCare Technologies (GEHC)$33.7B
Terumo (TRUMY)$26.6B
Koninklijke Philips (PHG)$26.6B
Insulet (PODD)$23.9B
Zimmer Biomet Holdings (ZBH)$21B
Smith & Nephew SNATS (SNN)$16.4B
Baxter (BAX)$12.7B
Sunny Optical Technology (SNPTF)$10.8B
Demant (WILYY)$8.1B
Bio-Rad Laboratories (BIO)$8.1B
Lantheus Holdings (LNTH)$3.7B
Envista Holdings (NVST)$3.5B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Prestige Consumer Healthcare (PBH)$3.3B
Perrigo (PRGO)$3.3B
ICU Medical (ICUI)$3.2B
Haemonetics (HAE)$2.6B
Acuren (TIC)$2.3B
Curaleaf Holdings (CURLF)$2.2B
LeMaitre Vascular (LMAT)$2.2B
QuidelOrtho (QDEL)$1.9B
Green Thumb Industries (GTBIF)$1.8B